HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
P9Xy8g2e3Q9tBR2N